Intravitreal anti–vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with age-related macular degeneration: A meta-analysis

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 4, 2016, Pages 1798-1806

  Shin, Hyun Jin ^a   Kim, Soo Nyung ^a   Chung, Hyewon ^a   Kim, Tae Eun ^a   Kim, Hyung Chan ^a  

^a Konkuk University Hospital   (South Korea)

Author keywords

Age related macular degeneration; Anti vascular endothelial growth factor; Retinal nerve fiber layer

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANTIANGIOGENIC THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); FOLLOW UP; HUMAN; META ANALYSIS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINAL NERVE FIBER LAYER LOSS; RETINAL NERVE FIBER LAYER THICKNESS; SCORING SYSTEM; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VISUAL SYSTEM PARAMETERS; VITRECTOMY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; METABOLISM; NERVE FIBER; PATHOLOGY; RETINA GANGLION CELL;

ANGIOGENESIS INHIBITORS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; NERVE FIBERS; RETINAL GANGLION CELLS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84963747267     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-18404     Document Type: Article

References (42)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004; 291: 1900-1901.
2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004; 122: 477-485.
3. Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell. 2010; 143: 13-16.
4. Rofagha S, Bhisitkul RB, Boyer DS, et al.; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120: 2292-2299.
5. Peden MC, Suñer IJ, Hammer ME, et al. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015; 122: 803-808.
6. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419-1431.
7. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148: 43-58.
8. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364: 1897-1908.
9. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age related macular degeneration. Ophthalmology. 2012; 119: 2537-2548.
10. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci. 1999; 19: 5731-5740.
11. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007; 171: 53-67.
12. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals. 2005; 14: 207-221.
13. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009; 40: 293-295.
14. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009; 23: 181-185.
15. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007; 27: 1044-1047.
16. Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008; 146: 930-934.
17. Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013; 182: 1379-1390.
18. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012; 53: 6214-6218.
19. Horsley MB, Mandava N, Maycotte MA, et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010; 150: 558-561.
20. Entezari M, Ramezani A, Yaseri M. Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration. J Ophthalmic Vis Res. 2014; 9: 449-452.
21. Shin HJ, Shin KC, Chung H, et al. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014; 55: 2403-2411.
22. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008-2012.
23. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 21: e1000097.
24. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. 3rd Symposium on Systematic Reviews: Beyond the Basics. 2000: 3-5.
25. Aziz O, Constantinides V, Tekkis PP, et al. Laparoscopic versus open surgery for rectal cancer: a meta-analysis. Ann Surg Oncol. 2006; 13: 413-424.
26. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002; 21: 1539-1558.
27. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101.
29. Sterne JA, Egger M. Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. J Clin Epidemiol. 2001; 54: 1046-1055.
30. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001; 323: 101-105.
31. Sobacı G, Güngör R, Ozge G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol. 2013; 18: 211-215.
32. Parlak M, Oner FH, Saatci AO. The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. Int Ophthalmol. 2015; 35: 473-480.
33. Demirel S, Batioğlu F, Özmert E, et al. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res. 2015; 40: 87-92.
34. El-Ashry MF, Lascaratos G, Dhillon B. Evaluation of the effect of intravitreal ranibizumab injections in patients with neovascular age related macular degeneration on retinal nerve fiber layer thickness using optical coherence tomography. Clin Ophthalmol. 2015; 13; 9: 1269-1274.
35. Rouvas A, Liarakos VS, Theodossiadis P, et al. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica. 2009; 223: 383-389.
36. Sung KR, Wollstein G, Bilonick RA, et al. Effects of age on optical coherence tomography measurements of healthy retinal nerve fiber layer, macula, and optic nerve head. Ophthalmology. 2009; 116: 1119-1124.
37. Girkin CA, McGwin G Jr, Sinai MJ, et al. Variation in optic nerve and macular structure with age and race with spectraldomain optical coherence tomography. Ophthalmology. 2011; 118: 2403-2408.
38. Bendschneider D, Tornow RP, Horn FK, et al. retinal nerve fiber layer thickness in normals measured by spectral domain OCT. J Glaucoma. 2010; 19: 475-482.
39. Zucchiatti I, Parodi MB, Pierro L, et al. Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration. Am J Ophthalmol. 2015; 160: 602-607.
40. Park CH, Lee KL, Park HY, et al. Changes in retinal nerve fiber layer after intravitreal injections of bevacizumab in glaucoma patients. J Korean Ophthalmol Soc. 2014; 55: 693-701.
41. Garcia-Martin E, Pueyo V, Ara JR, et al. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011; 17: 830-837.
42. Garcia-Martin E, Pablo LE, Herrero R, et al. Diagnostic ability of a linear discriminant function for spectral-domain optical coherence tomography in patients with multiple sclerosis. Ophthalmology. 2012; 119: 1705-1711.